Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
NCT05204160
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is testing a medicine called pembrolizumab to see if it helps people with a type of cancer called multiple myeloma. The cancer might be getting worse even after a treatment called CAR-T cell therapy. Pembrolizumab works by helping the body's own immune system fight the cancer and stopping the cancer from growing and spreading.
This study is testing a medicine called pembrolizumab to see if it helps people with a type of cancer called multiple myeloma. The cancer might be getting worse even after a treatment called CAR-T cell therapy. Pembrolizumab works by helping the body's own immune system fight the cancer and stopping the cancer from growing and spreading.
Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
